Key Leaders’ Opinion on Translational Lung Cancer Research

Posted On 2021-09-18 14:22:23
Key Leaders’ Opinion on Translational Lung Cancer Research
Editors: Desheng Xiao, Chunlin Ou, Pier Luigi Filosso, William W. Lockwood

Publisher: AME Publishing Company; 1st edition (2021)
ISBN: 978-988-74593-7-8
Hardcover: 195 pages
Language: English
Available at:

This book is an impressive international initiative in order to join the main worldwide key leader’s opinion to discuss the most recent advances in lung cancer field. The book addresses all the main related areas, such as the epidemiology and surveillance, cancer biology (oncogenes, signaling pathways, microRNA, LncRNA, exosomal ncRNA), chemotherapy and immunotherapy advances. This book is very important to research and clinicians who wants to update theirself regarding the main lung cancer aspects of disease. Herein, the readers will find interesting topics, such as SOX2 role in lung cancer, RASSF1A and YAP1 role in metastasis activation, the role of MetaLanc9 as a biomarker to lung cancer, Hippo pathway in lung cancer development, the interaction of microRNA and KRAS pathway in lung cancer, exomederived microRNA in cancer progression, alectinib role in first line ALK positive advanced NSCLC, osimertinib role in 1st line EGFR positive advanced NSCLC, inflammation and cancer, the future of immune checkpoint blockade immunotherapy, mechanisms of Epithelial-mesenchymal transition-induced metastasis and many others. Therefore, this book is a great opportunity to keep you updated regarding lung cancer issues and to improve the clinical practice and research worldwide in this field.


Desheng Xiao Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China
Chunlin Ou Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
Pier Luigi Filosso Department of Surgical Sciences, University of Torino, Torino, Italy
William W. Lockwood Department of Integrative Oncology, British Columbia Cancer Agency, Vancouver, Canada; Interdisciplinary Oncology Program, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada


Xiaoyun He Departments of Ultrasound Imaging, Xiangya Hospital, Central South University, Changsha, China
Ramon Andrade De Mello Algarve Biomedical Center, Department of Biomedical Sciences and Medicine, Division of Oncology, University of Algarve, Faro, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Translational Research Centre, Division of Medical Oncology, Oncology & Hematology Nucleus of Ceará, Hospital São Mateus, Fortaleza, CE, Brazil
Francesco Pezzella Division of Nuffield Clinical Laboratory Science, Department of Radcliffe Medicine, John Radcliffe Hospital, Headington, Oxford, UK
Sook-Hee Hong Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea